Free tool
Drugs in development
Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations
Drugs in development
3,685
Not FDA-approved
In Phase 3
1,424
Highest phase reached
Matching your filters
118
118 drugs in development
Names, sponsors and conditions come from the trial records. Click a drug for its trials.
- KJ101Phase 21 trial
Shanghai Bao Pharmaceuticals Co., Ltd. · Burn, Burn Wounds - Partial Thickness (2nd Degree)
- LEO 138559LEO 138559 is also called "temtokibart"Phase 21 trial
LEO Pharma · Atopic Dermatitis
- LY03015LPM3770164 sustained releasePhase 21 trial
Luye Pharma Group Ltd. · Tardive Dyskinesia (TD)
- N17350Phase 21 trial
Onchilles Pharma Inc · Neoplasms, Solid Tumor, Breast Neoplasms, Triple-Negative, Squamous Cell Carcinoma of Skin
- NBI-1065890Phase 21 trial
Neurocrine Biosciences · Tardive Dyskinesia
- OBX-115Phase 21 trial
Obsidian Therapeutics, Inc. · Tumor Skin, Metastatic Melanoma, Melanoma
- PF-07264660Phase 21 trial
Pfizer · Atopic Dermatitis
- PF-08049820Phase 21 trial
Pfizer · Atopic Dermatitis, Eczema, Atopic
- PN-101Phase 21 trial
Paean Biotechnology Inc. · Polymyositis, Dermatomyositis
- SIM0278Phase 21 trial
Jiangsu Simcere Pharmaceutical Co., Ltd. · Atopic Dermatitis (AD)
- SKX-16Luliconazole 10%Phase 21 trial
SATO Pharmaceutical Co., Ltd. · Onychomycosis of Toenails
- STMC-103HPhase 21 trial
Siolta Therapeutics, Inc. · Atopic Dermatitis, Type 1 Hypersensitivity
- TAVO101Phase 21 trial
Tavotek Biotherapeutics · Atopic Dermatitis
- TCP-25Phase 21 trial
Xinnate AB · Epidermolysis Bullosa (EB), Dystrophic Epidermolysis Bullosa, Junctional Epidermolysis Bullosa
- TRIV-509Phase 21 trial
Triveni Bio · Atopic Dermatitis
- TRIV-573Phase 21 trial
Triveni Bio · Atopic Dermatitis
- UCB1381Phase 21 trial
UCB · Atopic Dermatitis
- YR001Phase 21 trial
Hangzhou Yirui Pharmaceutical Technology Co., Ltd · Atopic Dermatitis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.